Organization
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
6 abstracts
Abstract
Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.Org: University of Hawaii Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center,
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.Org: Exact Sciences Corporation, Cancer Research and Biostatistics (CRAB), Seattle, WA, ASCO, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Loyola University Chicago Stritch School of Medicine,
Abstract
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Pfizer, Inc.,
Abstract
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.Org: Memorial Sloan Kettering Cancer Center, Stanford University Medical Center, Stanford, CA, Seoul National University Bundang Hospital, START Midwest, Grand Rapids, MI, Samsung Medical Center,
Abstract
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, The Sarah Cannon Research Institute, Division of Hematology/Oncology, Henry Ford Health System, Pfizer, Inc.,